![Invitae - Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust Invitae - Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust](https://mma.prnewswire.com/media/896492/Invitae_genetic_testing_Infographic.jpg)
Invitae - Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust
![Workflow for the Invitae Personalized Cancer Monitoring assay. This... | Download Scientific Diagram Workflow for the Invitae Personalized Cancer Monitoring assay. This... | Download Scientific Diagram](https://www.researchgate.net/publication/373428962/figure/fig1/AS:11431281183945947@1693140185473/Workflow-for-the-Invitae-Personalized-Cancer-Monitoring-assay-This-tumor-informed-assay.png)
Workflow for the Invitae Personalized Cancer Monitoring assay. This... | Download Scientific Diagram
Invitae - We've lowered our patient-pay panel price from $475 to $250 as part of our dedication to making high-quality genetic testing affordable. Our goal is to make genetic testing accessible to
![Invitae - Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening Invitae - Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening](https://mma.prnewswire.com/media/710184/Invitae_Corporation_Genetic_Testing.jpg)
Invitae - Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening
![Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) – enlightenbio Blog Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) – enlightenbio Blog](https://i0.wp.com/enlightenbio.com/wp-content/uploads/2020/09/Invitae.png?fit=740%2C224&ssl=1)
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) – enlightenbio Blog
![INVITAE CORPORATION: New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients | FDA Health News INVITAE CORPORATION: New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients | FDA Health News](https://s3.amazonaws.com/jnswire/jns-media/25/52/1280837/genetic.png)
INVITAE CORPORATION: New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients | FDA Health News
![Invitae Announces Second Quarter 2016 Financial Results, Secures Contract with a National Payer and Expands Its Network of Regional Private Payers | Business Wire Invitae Announces Second Quarter 2016 Financial Results, Secures Contract with a National Payer and Expands Its Network of Regional Private Payers | Business Wire](https://mms.businesswire.com/media/20160808006131/en/538534/5/NVTA_Q2-16_margins.jpg)